Ionis Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Ionis Pharmaceuticals generated cash of -$307,513,000, which is less than the previous year. Cash used in financing activities reached the amount of $644,082,000 last year. Net change in cash is therefore $122,794,000.
Cash Flow
| 2014 | 6.28M | -82.84M | 59.58M |
|---|---|---|---|
| 2015 | 21.12M | -60.05M | 24.72M |
| 2016 | -112.10M | 56.59M | 11.39M |
| 2017 | 174.14M | -358.29M | 229.08M |
| 2018 | 602.88M | -929.56M | 475.86M |
| 2019 | 345.72M | -41.27M | 100.02M |
| 2020 | 35.89M | 274.47M | -596.60M |
| 2021 | 30.79M | 194.90M | 245.93M |
| 2022 | -274.37M | -262.63M | -55.29M |
| 2023 | -307.51M | -214.12M | 644.08M |
0JDI.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 276.47M | 869.19M | 397.66M | 683.28M | 278.82M | 129.63M | 84.68M | 128.79M | 142.99M | 159.97M |
Operating activities | ||||||||||
Net income | -366.28M | -269.72M | -28.59M | -486.76M | 303.26M | 214.98M | -17.29M | -86.55M | -88.27M | -38.98M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 22.49M | 22.10M | 19.56M | 17.16M | 15.99M | 12.52M | 8.34M | 9.03M | 10.23M | 9.40M |
Stock-based compensation expense | 105.80M | 100.26M | 120.67M | 230.11M | 146.57M | 0 | 85.97M | 72.10M | 59.31M | 31.38M |
| Deferred income tax benefit | 105.80M | 100.26M | 120.67M | 230.11M | 146.57M | 0 | 85.97M | 72.10M | 59.31M | 31.38M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -72.05M | 36.35M | 5.05M | -22M | -44.17M | 514K | 15.72M | -89.36M | -14.11M | 9.77M |
Inventories | -6.39M | 2.77M | -2.84M | -1.26M | -5.41M | 1.4M | -2.49M | -590K | -609K | 1.74M |
Accounts payable | 8.11M | 1.09M | -6M | -2.75M | -16.34M | -655K | 1.78M | -10.67M | 9.21M | 4.82M |
Cash generated by operating activities | -307.51M | -274.37M | 30.79M | 35.89M | 345.72M | 602.88M | 174.14M | -112.10M | 21.12M | 6.28M |
Investing activities | ||||||||||
Purchases Of Investments | -1.77B | -1.48B | -1.13B | -1.57B | -1.95B | -1.79B | -880.31M | -300.91M | -493.46M | -391.88M |
Investments In Property Plant And Equipment | -23.80M | -20.09M | -17.90M | -41.04M | -36.28M | -17.65M | -37.85M | -11.52M | -11.74M | -11.10M |
Acquisitions Net | 0 | 254.08M | 5.94M | 5.92M | 5.37M | 4.04M | 2.50M | 4.46M | 25.52M | 22.94M |
Cash generated by investing activities | -214.12M | -262.63M | 194.90M | 274.47M | -41.27M | -929.56M | -358.29M | 56.59M | -60.05M | -82.84M |
Financing activities | ||||||||||
Common Stock Issued | 49.44M | 6.37M | 11.56M | 52.03M | 119.65M | 475.86M | 255.10M | 12.59M | 24.88M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -16.72M | -103.95M | -34.39M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 86.89M | -50.68M | -318.93M | 0 | 97M | 0 | -23.98M | -7.06M | -558K | -451.98M |
Cash used in financing activities | 644.08M | -55.29M | 245.93M | -596.60M | 100.02M | 475.86M | 229.08M | 11.39M | 24.72M | 59.58M |
Net Change In Cash | 122.79M | -592.71M | 471.52M | -285.62M | 404.46M | 149.19M | 44.94M | -44.11M | -14.20M | -16.97M |
Cash at end of period | 399.26M | 276.47M | 869.19M | 397.66M | 683.28M | 278.82M | 129.63M | 84.68M | 128.79M | 142.99M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |